Highlights

  • Orthocell (ASX:OCC) reports the highest single-month U.S. sales of Remplir since its American launch, signalling accelerating commercial traction.
  • The result reflects growing surgeon adoption and expanding distributor reach across multiple U.S. states, reinforcing the company's hybrid commercialisation model.
  • Remplir is approved in several markets including Australia, the U.S., Canada, Hong Kong, Singapore, and Thailand, with EU and UK regulatory submissions underway.
  • The U.S. Department of Defense and Veterans Affairs hospital network has been cleared as an additional avenue for Remplir use, broadening the addressable customer base.

Orthocell Limited (ASX:OCC), the Perth-headquartered regenerative medicine company, has disclosed its highest single month of U.S. commercial sales for its peripheral nerve repair device Remplir since the product's American launch. The milestone underscores the gathering pace of Orthocell's North American rollout and the increasing acceptance of its technology within a market the company estimates at approximately US$1.6 billion. The result is the outcome of a sustained commercial effort involving distributor network expansion, direct surgeon engagement, and hospital access programs that have been building throughout the year.

Record Month Signals Commercial Inflection

The record U.S. sales month reflects both deeper engagement with existing surgeon accounts and the successful onboarding of new hospital relationships. Over recent quarters, Orthocell has built a distributor network now spanning more than twenty U.S. states, covering close to half the national population, with an ambition to extend coverage to approximately 80 per cent. The company's strategy combines specialist external distributors with an in-house field Leadership team — a hybrid model that early data suggests is delivering results as surgeon familiarity with the product deepens. Remplir is a collagen-based nerve wrap device designed to support the repair and protection of peripheral nerves. It offers surgeons a less suture-intensive approach to nerve repair across a wide range of procedures, from facial nerve reconstruction to upper and lower limb surgery. Since its Australian market launch in late 2022, the product has been adopted by a growing community of orthopaedic and plastic surgeons across multiple geographies. In the United States alone, over 70 surgeons had used Remplir as at the most recent reporting period, a figure the company is targeting to increase substantially as distributor coverage expands.

Global Commercialisation Continues to Expand

Beyond the U.S., Orthocell has achieved initial commercial sales in Canada, Hong Kong, and Thailand, adding to its established base in Australia, New Zealand, and Singapore. Regulatory submission processes are advancing in both the European Union and the United Kingdom, with the company targeting market entry in those regions in the medium term. The breadth of the international approval pathway reflects the clinical confidence Orthocell has developed in Remplir's safety and efficacy profile. Real-world clinical data from Australian procedures, including an independently conducted study of outcomes in patients undergoing Remplir-assisted nerve repair, returned encouraging results with a high average efficacy rate. The company has also reported first surgical use of Remplir within the U.S. Department of Defense and Veterans Affairs hospital network following recent approval, opening a meaningful additional avenue within the large and under-penetrated American healthcare system. More than 55 hospitals have now purchased Remplir, and the number of surgeons who have used the device has expanded substantially since the U.S. launch, demonstrating the breadth of engagement the company has achieved within the world's largest healthcare market.

Sector Context and Market Dynamics

The peripheral nerve repair market represents a segment of broader surgical implant and regenerative medicine where unmet clinical need remains considerable. Traditional approaches relying heavily on suturing have well-documented limitations, creating Demand for devices that can improve patient outcomes and simplify surgical workflow. Remplir's collagen architecture is designed to address those limitations by creating a conducive healing environment while allowing natural gliding at the repair site during the recovery period. Orthocell also markets Striate+, a collagen dental matrix used in dental implant and periodontal procedures, through its commercial partner BioHorizons. Revenue from Striate+ has been growing steadily in recent periods, providing a complementary revenue stream that supports the company's financial sustainability while Remplir builds commercial scale. This dual-product portfolio distinguishes Orthocell from single-asset MedTech companies and provides a layer of commercial resilience. For the full year ended June 2026, Orthocell reported record revenue from ordinary activities, representing significant year-on-year growth driven in particular by Remplir's expanding contribution.

Financial Position and Strategic Outlook

Orthocell has maintained a well-capitalised Balance Sheet throughout its commercialisation phase, holding cash reserves that management has described as providing multiple years of operational runway. The company's Investment in its U.S. field team and distributor infrastructure has been financed from existing resources, avoiding material dilution during the critical early commercial period. A Research and Development tax incentive refund received during the year also provided a non-dilutive Capital contribution. Management has pointed to growing surgeon engagement and increasing case activity as the key drivers expected to sustain and extend the recent U.S. momentum. With EU and UK regulatory submissions progressing, and with expanding coverage in North America, the commercial horizon for Remplir continues to broaden. The company has also highlighted the potential for Remplir to be used in nerve-sparing prostate cancer surgery — an additional clinical application that, if pursued, could expand the total addressable market from the current estimate of US$1.6 billion.

Key Insights

Orthocell's record monthly U.S. Remplir sales reflect measurable progress in its strategy of building surgeon relationships and hospital access across North America. With an expanding international footprint, a complementary dental product line, and an EU/UK regulatory pathway underway, the company enters its next growth phase with both commercial traction and balance sheet capacity. The immediate challenge lies in converting the broadening footprint into sustained revenue at scale, particularly as the U.S. market continues to develop. The trajectory of surgeon adoption, hospital approvals, and distributor coverage expansion will be the metrics that best indicate whether the record month marks a durable inflection or a temporary high.